Sartorius Stedim Biotech (EPA: DIM) net income
Sartorius Stedim Biotech reported a net profit of €265.6m for fiscal 2025, 51.7% more than in fiscal 2024 (€175.1m). Its net margin was 9.0%. Earnings per share were €2.73.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | €265.6m | +51.7% | 9.0% | €2.73 |
| 2024 | €175.1m | −43.5% | 6.3% | €1.81 |
| 2023 | €309.7m | −64.7% | 11.2% | €3.36 |
| 2022 | €876.1m | +111.4% | 25.1% | €9.51 |
| 2021 | €414.4m | +23.4% | 14.4% | €4.50 |
| 2020 | €335.9m | — | 17.6% | €3.64 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of euros, except per-share amounts.
Questions about the net income of Sartorius Stedim Biotech
- How much did Sartorius Stedim Biotech earn in fiscal 2025?
- Sartorius Stedim Biotech reported a net profit of €265.6m for fiscal 2025. In fiscal 2024 it reported a net profit of €175.1m.
- What are the earnings per share of Sartorius Stedim Biotech?
- They were €2.73 in fiscal 2025, compared with €1.81 in fiscal 2024.
- What is the net margin of Sartorius Stedim Biotech?
- In fiscal 2025 its net profit was 9.0% of its revenue.
- What was the most profitable year for Sartorius Stedim Biotech?
- Of its last 6 fiscal years, fiscal 2022, with €876.1m.
- Where do the figures for Sartorius Stedim Biotech come from?
- From the report Sartorius Stedim Biotech files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Sartorius Stedim Biotech files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021. More on Sartorius Stedim Biotech: the Sartorius Stedim Biotech page · annual accounts · revenue.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.